Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
BACKGROUND
Clinicians need a simple yet accurate method to predict other-cause mortality to inform medical decision making for men with prostate cancer (PCa).


OBJECTIVE
To compare weighted and unweighted Charlson Comorbidity Index scores in predicting long-term, other-cause mortality in men with early-stage PCa.


DESIGN, SETTING, AND PARTICIPANTS
A retrospective cohort study of 1482 men with early-stage PCa diagnosed in 1998-2004 at two Southern California Veterans Affairs medical centers.


OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
Subhazard ratios and cumulative incidence of other-cause mortality associated with weighted and unweighted Charlson scores, calculated by competing-risks regression accounting for cancer mortality, along with Harrell concordance index (C-index) values.


RESULTS AND LIMITATIONS
Weighted and unweighted Charlson scores were identical in 88.6% of subjects (1313 of 1482 men) across all scores and in 91.7% of subjects (1359 of 1482 men) across scores of 0, 1, 2, and ≥3. In competing-risks analysis, hazards of other-cause mortality were similar when comparing weighted and unweighted scores. Men with weighted scores of 1, 2, and ≥3 (vs. 0) had subhazard ratios of 2.3 (95% confidence interval [CI], 1.6-3.2), 4.1 (95% CI, 2.9-5.8), and 8.3 (95% CI, 5.9-11.5), respectively. Men with unweighted scores of 1, 2, and ≥3 (vs. 0) had subhazard ratios of 2.5 (95% CI, 1.8-3.5), 4.5 (95% CI, 3.2-6.3), and 10.3 (95% CI, 7.2-14.7), respectively. The C-indexes for prediction of other-cause mortality were nearly identical for weighted scores (0.759 [95% CI, 0.715-0.780]) and unweighted scores (0.756 [95% CI, 0.717-0.780]). The difference in C-index between the two methods was -0.003 (95% CI, -0.01 to 0.004).


CONCLUSIONS
An unweighted Charlson score yields similar strength of association and variance in predicting long-term, other-cause mortality compared with a weighted Charlson score.


PATIENT SUMMARY
A simple count of major comorbidities provides similar accuracy to a weighted index in predicting death from other causes in men with early-stage prostate cancer.
['Daskivich|Timothy J|TJ|', 'Kwan|Lorna|L|', 'Dash|Atreya|A|', 'Greenfield|Sheldon|S|', 'Litwin|Mark S|MS|']
D000230:Adenocarcinoma D000368:Aged D002140:California D002423:Cause of Death D015897:Comorbidity D006305:Health Status Indicators D006801:Humans D008297:Male D008875:Middle Aged D009367:Neoplasm Staging D011237:Predictive Value of Tests D011471:Prostatic Neoplasms D012189:Retrospective Studies D013997:Time Factors
Prostate Comorbidity Outcome assessment Prostatic neoplasms Survival